Don’t miss – Page 160 – Endpoints News

SIGN UP

In a fresh blow, Biogen loses a big court fight with Mylan over its blockbuster Tecfidera patent

3 years ago

As BioMarin’s lead rival wanes, Pfizer and Sangamo post a promising update for hemophilia A gene therapy

3 years ago

Covid-19 roundup: Roche's Actemra marred by negative results; Here comes another single-armed remdesivir trial

3 years ago

Chinese vaccine developers have begun to shed some secrecy around Covid-19 candidates. What do we know?

3 years ago

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

3 years ago

Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda

3 years ago

A Bay Area upstart with legendary godfathers breaks cover, touting claims of a curative tech, unicorn status and a $300M plan to shoot for an approval

3 years ago

Adding billions in value, Eli Lilly succeeds where Pfizer failed, halting breast cancer recurrence

3 years ago

Takeda spins out a pipeline of ‘interesting but still difficult’ psych drugs in $2B deal as it wraps up a post-merger R&D shakeout

3 years ago

Billions on the table, GSK’s Hal Barron antes $120M cash to partner with a specialist in synthetic lethality

3 years ago

Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors

3 years ago

On a hiring spree, Moderna recruits another Amgen vet for the executive committee; Repare, Forma set terms for IPO

3 years ago

Momenta clears a PhII hurdle on nipo — but one big rival remains well in the lead in this packed field

3 years ago

Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention

3 years ago

Sinovac posts positive PhI/II data for their Covid-19 vaccine as researchers rush into a pivotal test

3 years ago

Moderna burnishes its PhIII-ready Covid-19 vaccine with promising mouse data — which suggest one dose might be enough after all

3 years ago

Vertex and CRISPR spotlight another important gene editing advance in a march to a hoped-for cure

3 years ago

It's all about the heart: Diabetes major Novo Nordisk bets $725M upfront to buy cardio-focused AstraZeneca spinoff

3 years ago

Moderna floors it into PhIII with their Covid-19 vaccine, planning quick start with a thumbs-up from FDA on trial design, dosage

3 years ago

Covid-19 roundup: Regeneron puts its antibodies into the clinic, racing with Eli Lilly for fall authorization

3 years ago

'Tremendous' animal data inspire GV, ARCH's $63M booster for Sekar Kathiresan's drive to relegate coronary heart disease to history

3 years ago

Sanofi sharpens focus on bispecifics, and China, with Alphamab deal

3 years ago

Fujifilm doubles down on ex-Biogen facility with $928M infusion as biotech boom fuels CDMO growth

3 years ago

Analysts cheer as AbbVie pays $750M cash to ally itself with Genmab on a pipeline of cancer drugs, with billions more on the table

3 years ago

First page Previous page 157 158 159160161 162 163 Next page Last page